Interphase FISH as a new tool in tumor pathology

Cytogenetic and Genome Research

Volumn 118, Issue 2-4, 2007, Pages 229-236

  Tibiletti, M G ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROCHROME; MONOCLONAL ANTIBODY; PANITUMUMAB; TRASTUZUMAB;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CELL NUCLEUS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME IDENTIFICATION; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; LUNG CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

CHROMOSOME ABERRATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MOLECULAR PROBES; NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 36248968768     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108305     Document Type: Review

References (30)

1. Bast CR, Ravdin P, Hayes DF, Bates S, Fritsche H, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 196:1865-1878 (2001).
2. Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C, et al: Incidence of chromosome 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 190:530-539 (2000).
3. Dal Cin P, Van den Berghe H: Bone and soft tissue tumors. Cancer Genet Cytogenet 95:59-66 (1997).
4. Di Leo A, Dowsett M, Horten B, Penault-Llorca F: Current status of HER2 testing. Oncology 63:25-32 (2002).
5. Farabegoli F, Santini D, Maccarelli C, Taffurelli M, Marrano D, Baldini N: Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 46:50-56 (2001).
6. Fornier M, Risio M, Van Poznak C, Seidman A: HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology 16:1340-1358 (2002).
7. Gibas Z, Gibas L: Cytogenetics of bladder cancer. Cancer Genet Cytogenet 95:108-115 (1997).
8. Hammond MEH, Barker P, Taube S, Gutman S: Standard reference material for Her2 testing. Appl Immunohistochem Mol Morphol 112:103-106 (2003).
9. Hruban RH, Goggins M, Pearson J, Kern SE: Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972 (2000).
10. ISCN (2005): An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N (eds) (S Karger, Basel 2005).
11. Ishiwata S, Takahahashi S, Homma Y, Tanaka Y, Kameyama S, et al: Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization, analysis of exfoliated urothelial cells in voided urine. Urology 574:811-815 (2001).
12. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification. Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, Lyon 2002).
13. Junker K, Werner W, Mueller C, Ebert W, Schubert J, Claussen U: Interphase cytogenetic diagnosis of bladder cancer on cells from urine and bladder washing. Int J Oncol 142:309-313 (1999).
14. Kobayashi M, Ooi A, Oda Y, Nakanishi I: Protein overexpression and gene amplification of c-erb-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed paraffin-embedded tissues. Hum Pathol 33:21-28 (2002).
15. Kontogeorgos G, Kapranos N, Orphanidis G, Rologis D, Kokka E: Molecular cytogenetics of chromosome 11 in pituitary adenomas: a comparison of fluorescence in situ hybridization and DNA ploidy study. Human Pathol 30:1377-1382 (1999).
16. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, et al: HER2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363 (2001).
17. Liehr T, Grehel H, Rautenstraus B: FISH analyses of interphase nuclei extracted from paraffin-embedded tissue. Trends Genet 11:377-378 (1995).
18. Look AT: Genes altered by chromosomal translocations in leukaemia and lymphomas, in Vogelstein B, Kinzler KV (eds): The Genetic Basis of Human Cancer (McGraw Hill, Columbus 1998).
19. Mitelman F: Catalog of Chromosome Aberrations in Cancer. 7 th Ed (Wiley-Liss, New York 1994).
20. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al: Gene copy number of epidermal growth factor receptor ( EGFR ) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-86 (2005).
21. Nielsen PE, Egholm M (eds): Peptide Nucleic Acids Protocols and Applications (Horizon Scientific Press, Norfolk 1999).
22. Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW: A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 160:1967-1972 (2002).
23. Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quantitative high-sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 83:2934-2938 (1986).
24. Sequist LV, Haber DA, Lynch TJ: Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res 11:5668-5670 (2005).
25. Thompson CT, LeBoit PE, Nederlof PM, Gray JW: Thick section fluorescence in situ hybridization on formalin-fixed paraffin-embedded archival tissue provides a histogenetic profile. Am J Pathol 144:237-243 (1994).
26. Tibiletti MG: Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology. Cancer Genet Cytogenet 155:143-148 (2004).
27. Tibiletti MG, Bernasconi B, Dionigi A, Riva C: The applications of FISH in tumor pathology. Adv Clin Path 3:111-118 (1999).
28. Tibiletti MG, Sessa F, Bernasconi B, Cerutti R, Brogli B, et al: A large 6q deletion is a common cytogenetic alteration in fibroadenomas pre-malignant lesions and carcinomas of the breast. Clin Cancer Res 6:1422-1431 (2000).
29. Tibiletti MG, Bernasconi B, Furlan D, Bressan P, Cerutti R, et al: Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms. Clin Cancer Res 7:3404-3409 (2001).
30. Tibiletti MG, Bernasconi B, Taborelli M, Facco C, Riva C, et al: Genetic and cytogenetic observations among different types of ovarian tumors are compatible with progression model underlying ovarian tumorigenesis. Cancer Genet Cytogenet 146:145-153 (2003).